Portage Biotech is a clinical-stage biopharmaceutical company developing first-in-class immuno-oncology therapies that target known checkpoint resistance pathways to enhance durable treatment responses in cancer patients. By leveraging a diverse portfolio of drug platforms and a robust industry network, the company aims to improve patient quality of life through innovative asset combinations and strategic drug development.
Funding
$6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Despite advances in immuno-oncology, a significant percentage of cancer patients, approximately 70-80%, exhibit limited or no response to existing therapies like checkpoint inhibitors. This lack of response underscores the need for novel therapeutic approaches that can overcome resistance mechanisms and enhance treatment efficacy.
Solution
Portage Biotech is developing first-in-class immuno-oncology therapies that target known checkpoint resistance pathways to improve durable treatment responses and quality of life for cancer patients. The company leverages a diverse portfolio of drug platforms and a network of industry partnerships to identify and advance novel assets and asset combinations. Portage Biotech actively manages the drug development process, providing strategic guidance to advance immunotherapy assets from preclinical stages through human proof-of-concept studies. Their approach involves efficient capital management and scientific oversight, with a "fail-fast" methodology to continuously evaluate and select the most promising therapeutic candidates for advancement.
Target Audience
The primary target audience includes cancer patients who are unresponsive or have limited response to current immuno-oncology treatments, as well as pharmaceutical companies seeking innovative assets for oncology drug development.
Features
- Diverse portfolio of drug platforms targeting various cancer resistance pathways.
- Focus on first-in-class immuno-oncology therapies.
- Strategic guidance for novel immunotherapy assets from bench to clinical trials.
- Efficient capital management and scientific oversight to de-risk clinical development.
- "Fail-fast" approach to continuously review and select promising therapeutic candidates.